Sentence examples for maintenance therapy achieved from inspiring English sources

The response rate for second-line treatment was similar between the R-maintenance and observation groups; 61% of patients who received maintenance therapy achieved a CR/PR with second-line treatment versus 57% in the observation arm (Table 4).

A phase III trial, the European Infliximab for Psoriasis Efficacy and Safety Study (EXPRESS), of infliximab at a dose of 5 mg/kg at 0, 2 and 6 weeks followed by 8 week maintenance therapy achieved PASI 75 in 82% of patients at week 24.

Repeat kidney biopsies in patients on maintenance therapy who achieved and maintained a complete clinical response for several years still showed histologically active LN in 30 60% of individuals [ 49].

Two smaller retrospective studies have addressed RTX as maintenance therapy after achieving remission [ 15, 16], both reporting successful results with less frequent relapses.

Those receiving the behavioral placebo therapy achieved a 12percentt reduction.

One patient with metastatic breast cancer, whose disease progressed on the right chest wall around the previous mastectomy scar while on maintenance therapy with trastuzumab, achieved CR following combination therapy with MK-2206.

Moreover, both P3 target antigen and PR1-CTL were found to be increased in CML patients that continued in CCR while receiving IFN as a single agent maintenance therapy after first achieving CCR during upfront treatment with IFN plus the bcr-abl tyrosine kinase inhibitor imatinib mesylate [29].

Some trials reduced doses for maintenance therapy when remission was achieved, whereas in two [ 55, 56], the mean daily doses were 2.7 and 1.6 g, respectively, without tailing.

Oral VOR and POS therapies achieved clinical responses as the maintenance of antifungal therapy in 16 and 18 patients, respectively, at least 4 weeks after systemic antifungal therapy without toxicity or discontinuation.

AZA and MTX are effective as maintenance therapy once remission has been achieved.

The question being addressed is whether DRV/r monotherapy can be used as a maintenance therapy once the patient has achieved an undetectable viremia with a standard approved combination therapy.